Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis

2021 ◽  
Author(s):  
Samin Hajian ◽  
Mehrdokht Mazdeh ◽  
Fatemeh Nouri ◽  
Ghodratollah Roshanaei ◽  
Meysam Soleimani
Keyword(s):  
Multiple Sclerosis ◽  
Association Study ◽  
Interferon Alpha ◽  
Interferon Beta ◽  
Therapeutic Response ◽  
Receptor Subunit ◽  
Promoter Polymorphisms ◽  
Beta Receptor

Analysis of Association Between Genetic Heterogeneity of Interferon Beta Receptor Promoter and Therapeutic Response to Interferon-beta in a Patient with Multiple Sclerosis

2021 ◽  
Author(s):  
Samin Hajian ◽  
Mehrdokht Mazdeh ◽  
Fatemeh Nouri ◽  
Meysam Soleimani
Keyword(s):  
Multiple Sclerosis ◽  
Genetic Heterogeneity ◽  
Interferon Beta ◽  
P Value ◽  
Promoter Polymorphisms ◽  
Beta Receptor ◽  
Sequencing Method ◽  
Significant Difference ◽  
Disability Status ◽  
Larger Sample

Abstract Multiple sclerosis (MS) is an autoimmune disease characterized by inflammatory neuronal damages and consequent disabilities. Episodic relapses of the disease could be decreased by the interferon-beta (IFN-β) therapy in most MS patients. However, the drug response’s efficiency is variable among patients, and the precise mechanism of action of the IFN-β is not clear. This study aimed to investigate the interferon beta-receptor (IFNAR) promoter polymorphisms on response to interferon beta in MS patients. Patients were divided into either responding (n = 57) or non-responding (n = 43) groups according to interferon beta treatment and Expanded Disability Status Scale score. The Sanger sequencing method is used for genotyping. Here, we found a significant association between 65 SNP in responders and non-responders to interferon beta (p-value < 0.05). The results also showed a significant difference between the two groups of responders and non-responders to the treatment in the presence or absence of insertion before GT repeat dinucleotide microsatellite (p-value < 0.02). The present study’s obtained results suggested the genetic heterogeneity in the promoter region of IFNAR can affect response to IFN-β. However, more studies with a larger sample size are needed to demonstrate this relationship further.

Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta

2020 ◽  
Vol 785 ◽  
pp. 108322 ◽  
Author(s):  
Laura Martínez-Aguilar ◽  
Cristina Pérez-Ramírez ◽  
María del Mar Maldonado-Montoro ◽  
María Isabel Carrasco-Campos ◽  
Cristina Membrive-Jiménez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Genetic Polymorphisms ◽  
Interferon Beta ◽  
Therapeutic Response ◽  
Relapsing Remitting

Systemic blocking of the interferon-alpha/beta receptor subunit 1 stimulates arteriogenesis without exacerbating atherosclerosis

2014 ◽  
Vol 235 (2) ◽  
pp. e27-e28
Author(s):  
M. Boshuizen ◽  
P. Teunissen ◽  
M. Hollander ◽  
N. van der Hoeven ◽  
S. van der Velden ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Receptor Subunit ◽  
Beta Receptor ◽  
Alpha Beta

scholarly journals IL-7Ra Association and Genotype-Dependent Severity and Response to IFN-β Therapy in Multiple Sclerosis

2019 ◽  
Author(s):  
Majid Hosseinzadeh ◽  
Parvin Aminoshareah ◽  
Mahmoud Mohammadi ◽  
Ali Reza Tavasoli ◽  
Mahdi Zamani
Keyword(s):  
Multiple Sclerosis ◽  
Neurodegenerative Disease ◽  
Therapeutic Effect ◽  
Genetic Factors ◽  
Interferon Beta ◽  
Therapeutic Response ◽  
Healthy Controls ◽  
Medical Sciences

Multiple sclerosis (MS) is a neurodegenerative disease arising from interactions of both environmental and genetic factors. The SNP rs6897932 is located in IL‐7Ra gene associated with MS susceptibility in some population. In this study, we investigated the possible association of SNP rs6897932 with MS susceptibility in 157 Iranian MS patients and 152 healthy controls. We also studied genotype-dependent severity and response to IFN-β in MS. Unlike some previous studies, our results clearly demonstrate that there are no significant differences in distribution of the SNP rs6897932 in our chosen Iranian MS patients and controls. Furthermore our results show, Interferon beta (IFN-β) therapy over a period of two years demonstrated an IL‐7Ra genotype-dependent therapeutic effect in MS population. Patients carrying TT or TC genotypes gave a better response to IFN-β treatment, whereas patients carrying the homozygous CC genotype were the worst responders to IFN-β treatment. In other words, despite the lack of linkage the therapeutic response to the severity and progression of MS was related to the genotype of SNP rs6897932 presented in our patient. Therefore, in light of our findings reported here, to reach higher certainties, further studies are needed to associate IL-7Ra gene with the pathogenesis of MS. © 2019 Tehran University of Medical Sciences. All rights reserved. Acta Med Iran 2019;57(4):208-215.

Sign in / Sign up

Export Citation Format

Share Document